DUGGAN ROBERT W 4/A

4/A · PULSE BIOSCIENCES, INC. · Filed May 15, 2026

AI-generated summary of this filing

Updated May 15, 2026

Pulse Biosciences (PLSE) 10% Owner Robert W. Duggan Buys Shares

What Happened

Robert W. Duggan, a 10% owner of Pulse Biosciences (PLSE), purchased 660,233 shares on May 11, 2026 at $19.69 per share for a total of $12,999,988. The transaction is reported on an amended Form 4 filed May 15, 2026. This was a purchase (acquisition) rather than a sale.

Key Details

Transaction date and price: May 11, 2026 — 660,233 shares at $19.69 each; total value $12,999,988.
How shares were acquired: Purchased through the company’s at-the-market (ATM) equity offering program (per footnotes), at the prevailing market bid price or better.
Filing status: Amended Form 4 filed May 15, 2026 reporting the May 11 transaction.
Entity holdings: Some reported shares are held via entities (Genius 24C Inc. and Blazon Corporation) for which the reporting person is sole shareholder (per footnotes).
Other notes: Footnotes state the purchases occurred during an open trading window and reference ~700 shares inadvertently not reported in a Schedule 14A filing.

Context

As a 10% owner (not a routine employee trade), this is a large-owner purchase reported directly by the beneficial owner. The acquisition was executed through the company’s ATM program (sales agent: TD Securities (USA) LLC), meaning shares were bought in the open market under the ATM offering rather than via a private transfer or option exercise.

Form 4/AAmended

Period: 2026-05-11

Director10% Owner

Transactions

Purchase
Common Stock
[F1][F2][F3]
2026-05-11$19.69/sh+660,233$12,999,988→ 48,370,047 total

Holdings

Footnotes (5)

[F1]The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
[F2]The shares reported herein were acquired through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.
[F3]Includes approximately 700 shares inadvertently not reported in the Company's Schedule 14A filed on May 11, 2026.
[F4]Shares are held by Genius 24C Inc., of which the Reporting Person is the sole shareholder.
[F5]Shares are held by Blazon Corporation, of which the Reporting Person is the sole shareholder.

Signature

/s/ Kenneth B. Stratton, as Attorney-in-Fact|2026-05-15

1 file